Literature DB >> 15262202

Combined cyclosporine-A and methylprednisolone treatment exerts partial and transient neuroprotection against ischemic stroke.

Guolong Yu1, David C Hess, Cesario V Borlongan.   

Abstract

We investigated the neuroprotective effects of immunosuppressant cyclosporine-A (CsA) and the anti-inflammatory methylprednisolone (MP) in a stroke model. Adult Sprague-Dawley rats underwent middle cerebral artery (MCA) occlusion then were randomly treated with either: low dose CsA, MP, low dose CsA plus MP, high dose CsA, or vehicle. Ischemic animals that received low dose CsA, MP or vehicle displayed profound motor and neurological impairments at days 1-3 after stroke. In contrast, ischemic animals that received high dose CsA exhibited near normal motor and neurological functions throughout the test period. Of note, ischemic animals that received low dose CsA plus MP showed significantly less motor and neurological deficits at day 1, but thereafter displayed behavioral impairments. Histological analysis at 3 days post-stroke revealed that only those ischemic animals treated with high dose CsA had significantly reduced cerebral infarcts. This study is the first report to demonstrate partial and transient neuroprotection against stroke by low dose CsA when combined with MP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262202     DOI: 10.1016/j.brainres.2004.05.056

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Nanoparticles for targeted delivery of antioxidant enzymes to the brain after cerebral ischemia and reperfusion injury.

Authors:  Xiang Yun; Victor D Maximov; Jin Yu; Hong Zhu; Alexey A Vertegel; Mark S Kindy
Journal:  J Cereb Blood Flow Metab       Date:  2013-02-06       Impact factor: 6.200

2.  Human neural stem cells improve early stage stroke outcome in delayed tissue plasminogen activator-treated aged stroke brains.

Authors:  Austin C Boese; Auston Eckert; Milton H Hamblin; Jean-Pyo Lee
Journal:  Exp Neurol       Date:  2020-03-05       Impact factor: 5.330

Review 3.  Role of microglia in ischemic focal stroke and recovery: focus on Toll-like receptors.

Authors:  Jenni E Anttila; Keith W Whitaker; Emily S Wires; Brandon K Harvey; Mikko Airavaara
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-07-04       Impact factor: 5.067

4.  Effect of cyclosporin A on functional recovery in the spinal cord following contusion injury.

Authors:  Siobhan S McMahon; Silke Albermann; Gemma E Rooney; Cathal Moran; Jacqueline Hynes; Yolanda Garcia; Peter Dockery; Timothy O'Brien; Anthony J Windebank; Frank P Barry
Journal:  J Anat       Date:  2009-06-24       Impact factor: 2.610

Review 5.  Treatment of acute cerebral ischemia using animal models: a meta-analysis.

Authors:  Peng-Fei Wang; Yu Zhou; Huang Fang; Sen Lin; Yan-Chun Wang; Yong Liu; Jun Xia; Guy D Eslick; Qing-Wu Yang
Journal:  Transl Neurosci       Date:  2015-02-11       Impact factor: 1.757

Review 6.  Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke.

Authors:  Aldo Bonaventura; Luca Liberale; Alessandra Vecchié; Matteo Casula; Federico Carbone; Franco Dallegri; Fabrizio Montecucco
Journal:  Int J Mol Sci       Date:  2016-11-25       Impact factor: 5.923

7.  Dose and timing of injections for effective cyclosporine A pretreatment before renal ischemia reperfusion in mice.

Authors:  Sandrine Lemoine; Bruno Pillot; Lionel Augeul; Maud Rabeyrin; Annie Varennes; Gabrielle Normand; Delphine Baetz; Michel Ovize; Laurent Juillard
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

8.  Cyclosporin A ameliorates cerebral oxidative metabolism and infarct size in the endothelin-1 rat model of transient cerebral ischaemia.

Authors:  Axel Forsse; Troels Halfeld Nielsen; Kevin Heebøll Nygaard; Carl-Henrik Nordström; Jan Bert Gramsbergen; Frantz Rom Poulsen
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

9.  Protopanaxadiol ginsenoside Rd protects against NMDA receptor-mediated excitotoxicity by attenuating calcineurin-regulated DAPK1 activity.

Authors:  Chen Zhang; Xuedong Liu; Hui Xu; Gengyao Hu; Xiao Zhang; Zhen Xie; Dongyun Feng; Rui Wu; Gang Zhao; Ming Shi
Journal:  Sci Rep       Date:  2020-05-15       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.